GGHC
NKTR icon

Gilder Gagnon Howe & Co’s Nektar Therapeutics NKTR Stock Holding History

Gilder Gagnon Howe & Co’s Portfolio NKTR Stock Details NKTR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$41.9M Buy
600,873
+329,115
+121% +$24.1M 0.43% 66
2026
Q1 		$19.6M Buy
271,758
+63,456
+30% +$3.61M 0.23% 88
2025
Q4 		$8.81M Sell
208,302
-16,526
-7% -$925K 0.09% 121
2025
Q3 		$12.8M Buy
224,828
+195,926
+678% +$6.49M 0.13% 109
2025
Q2 		$747K Buy
28,902
+1,410
+5% +$15.8K 0.01% 209
2025
Q1 		$280K Buy
+27,492
New +$359K ﹤0.01% 224

Other funds holding NKTR

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
TSC
Two Seas Capital Rye, New York $5.05B AUM 164.99% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
VPC
Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Gilder Gagnon Howe & Co's NKTR Position: Q2 2026 in Review

Gilder Gagnon Howe & Co increased its Nektar Therapeutics (NKTR) stake by 121% in Q2 2026, buying an estimated $24.1M and bringing the position to 600,873 shares worth $41.9M. The position accounts for 0.43% of the portfolio, ranked #66.

Gilder Gagnon Howe & Co first reported a position in NKTR in Q1 2025 and has held it in 6 quarters since. 239 funds tracked by Wall St. Rank hold NKTR as of Q2 2026.

  • Gilder Gagnon Howe & Co held 600,873 shares of Nektar Therapeutics worth $41.9M as of Q2 2026.
  • Gilder Gagnon Howe & Co bought 329,115 Nektar Therapeutics shares in Q2 2026, an estimated $24.1M.
  • Nektar Therapeutics made up 0.43% of Gilder Gagnon Howe & Co's portfolio in Q2 2026, its #66 holding.
  • Gilder Gagnon Howe & Co first reported a position in Nektar Therapeutics in Q1 2025 and has held it in 6 quarters since.
  • 239 funds tracked by Wall St. Rank held Nektar Therapeutics as of Q2 2026.

Based on Gilder Gagnon Howe & Co's 13F filing for Q2 2026, filed 14 Aug 2026.